Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed MM
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed MM
The clinical value of maintenance in multiple myeloma
Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non-refractory multiple myeloma patients
Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM
Latest updates in exon 20 insertions focusing on targeted therapies, novel approaches, and implications for patients
PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible patients with muscle-invasive bladder cancer
JAVELIN Bladder 100: Avelumab first-line maintenance plus best supportive care (BSC) versus BSC alone for advanced UC
Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hodgkin’s lymphoma
Advances in lung cancer and current situation in Romania
First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukaemia
Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic leukaemia
EHA 2021: Latest in immunotherapy for R/R multiple myeloma